Does the media prefer TCRX or ERNA?

In the previous week, Ernexa Therapeutics had 4 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 3 mentions for TScan Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.33 beat TScan Therapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ernexa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, RADX or ERNA?

Ernexa Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 11.82 -$37.43M N/A N/A Ernexa Therapeutics $580K 8.73 -$14.08M -$14.35 N/A

Is RADX or ERNA more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Ernexa Therapeutics N/A -305.93% -169.86%

Is ATOS or ERNA more profitable?

Atossa Genetics' return on equity of -102.99% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Ernexa Therapeutics N/A -305.93% -169.86%

Does the media favor ATOS or ERNA?

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 4 mentions for Atossa Genetics. Ernexa Therapeutics' average media sentiment score of 0.33 beat Atossa Genetics' score of 0.25 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ernexa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ERNA or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Estrella Immunopharma N/A N/A -328.72%

Does the media favor ERNA or ESLA?

In the previous week, Ernexa Therapeutics had 6 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.91 beat Ernexa Therapeutics' score of 0.33 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JSPR or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Ernexa Therapeutics N/A -305.93% -169.86%

Ernexa Therapeutics (ERNA) Competitors

$3.19 +0.23 (+7.87%)

As of 10:30 AM Eastern

Compare

ERNA vs. TCRX, RADX, ATOS, ESLA, and JSPR

Should you buy Ernexa Therapeutics stock or one of its competitors? Ernexa Therapeutics's main competitors and comparable companies include TScan Therapeutics (TCRX), Radiopharm Theranostics (RADX), Atossa Genetics (ATOS), Estrella Immunopharma (ESLA), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ernexa Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

TScan Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.64, suggesting that its share price is 164% more volatile than the broader market.

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Ernexa Therapeutics had 4 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 3 mentions for TScan Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.33 beat TScan Therapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TScan Therapeutics presently has a consensus target price of $2.67, indicating a potential upside of 715.49%. Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 866.18%. Given Ernexa Therapeutics' higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Ernexa Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	2.15	-$129.77M	-$0.91	N/A
Ernexa Therapeutics	$580K	8.73	-$14.08M	-$14.35	N/A

Summary

TScan Therapeutics and Ernexa Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Ernexa Therapeutics had 7 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 0 mentions for Radiopharm Theranostics. Ernexa Therapeutics' average media sentiment score of 0.33 beat Radiopharm Theranostics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Ernexa Therapeutics	Neutral

70.6% of Ernexa Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Radiopharm Theranostics has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.64, meaning that its stock price is 164% more volatile than the broader market.

Radiopharm Theranostics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Ernexa Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	11.82	-$37.43M	N/A	N/A
Ernexa Therapeutics	$580K	8.73	-$14.08M	-$14.35	N/A

Radiopharm Theranostics presently has a consensus target price of $11.00, suggesting a potential upside of 677.39%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 866.18%. Given Ernexa Therapeutics' higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics beats Radiopharm Theranostics on 7 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Atossa Genetics' return on equity of -102.99% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Atossa Genetics has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the broader market.

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 4 mentions for Atossa Genetics. Ernexa Therapeutics' average media sentiment score of 0.33 beat Atossa Genetics' score of 0.25 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atossa Genetics presently has a consensus price target of $20.33, indicating a potential upside of 809.77%. Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 866.18%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Ernexa Therapeutics	$580K	8.73	-$14.08M	-$14.35	N/A

Summary

Ernexa Therapeutics beats Atossa Genetics on 8 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Estrella Immunopharma?

Ernexa Therapeutics (NASDAQ:ERNA) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ernexa Therapeutics has a beta of 2.64, suggesting that its share price is 164% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Estrella Immunopharma has lower revenue, but higher earnings than Ernexa Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	8.73	-$14.08M	-$14.35	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

In the previous week, Ernexa Therapeutics had 6 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.91 beat Ernexa Therapeutics' score of 0.33 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Estrella Immunopharma	N/A	N/A	-328.72%

Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 866.18%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,584.21%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics and Estrella Immunopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Ernexa Therapeutics has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Ernexa Therapeutics	$580K	8.73	-$14.08M	-$14.35	N/A

Jasper Therapeutics currently has a consensus target price of $7.33, suggesting a potential upside of 1,128.36%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 866.18%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Jasper Therapeutics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jasper Therapeutics has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the broader market.

In the previous week, Ernexa Therapeutics had 7 more articles in the media than Jasper Therapeutics. MarketBeat recorded 7 mentions for Ernexa Therapeutics and 0 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.68 beat Ernexa Therapeutics' score of 0.33 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
Ernexa Therapeutics	Neutral

Ernexa Therapeutics' return on equity of -305.93% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Summary

Jasper Therapeutics beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.02M	$3.93B	$7.22B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-0.21	13.45	272.64	25.80
Price / Sales	8.73	1,294.15	607.49	90.99
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	0.41	16.65	10.88	6.26
Net Income	-$14.08M	-$22.67M	$3.50B	$360.95M
7 Day Performance	-11.01%	-2.45%	-2.03%	-1.81%
1 Month Performance	-31.61%	-10.31%	-6.43%	-4.03%
1 Year Performance	-89.78%	21.98%	8.95%	2.18%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	3.3819 of 5 stars	$3.19 +7.9%	$30.00 +839.6%	-89.6%	$5.16M	$580K	N/A	5
TCRX TScan Therapeutics	2.9817 of 5 stars	$0.36 +2.6%	$2.67 +632.6%	-84.8%	$24.05M	$10.32M	N/A	142	News Coverage
RADX Radiopharm Theranostics	1.8584 of 5 stars	$1.63 -1.5%	$11.00 +576.9%	-74.2%	$23.86M	$1.88M	N/A	14	Gap Down
ATOS Atossa Genetics	2.2241 of 5 stars	$2.18 -3.5%	$20.33 +832.7%	-83.5%	$22.55M	N/A	N/A	14	News Coverage
ESLA Estrella Immunopharma	1.7362 of 5 stars	$0.47 -2.7%	$8.00 +1,594.9%	-64.6%	$21.10M	N/A	N/A	N/A	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. TCRX, RADX, ATOS, ESLA, and JSPR

How does Ernexa Therapeutics compare to TScan Therapeutics?

Summary

How does Ernexa Therapeutics compare to Radiopharm Theranostics?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Summary

How does Ernexa Therapeutics compare to Estrella Immunopharma?

Summary

How does Ernexa Therapeutics compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. TCRX, RADX, ATOS, ESLA, and JSPR

How does Ernexa Therapeutics compare to TScan Therapeutics?

Which has more risk & volatility, TCRX or ERNA?

Do institutionals and insiders believe in TCRX or ERNA?

Does the media prefer TCRX or ERNA?

Do analysts prefer TCRX or ERNA?

Is TCRX or ERNA more profitable?

Which has better earnings and valuation, TCRX or ERNA?

Summary

How does Ernexa Therapeutics compare to Radiopharm Theranostics?

Does the media refer more to RADX or ERNA?

Do institutionals and insiders hold more shares of RADX or ERNA?

Which has more volatility & risk, RADX or ERNA?

Is RADX or ERNA more profitable?

Which has better earnings & valuation, RADX or ERNA?

Do analysts prefer RADX or ERNA?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Is ATOS or ERNA more profitable?

Do institutionals & insiders have more ownership in ATOS or ERNA?

Which has more risk & volatility, ATOS or ERNA?

Does the media favor ATOS or ERNA?

Do analysts prefer ATOS or ERNA?

Which has preferable earnings & valuation, ATOS or ERNA?

Summary

How does Ernexa Therapeutics compare to Estrella Immunopharma?

Do insiders & institutionals believe in ERNA or ESLA?

Which has more volatility and risk, ERNA or ESLA?

Which has preferable valuation and earnings, ERNA or ESLA?

Does the media favor ERNA or ESLA?

Is ERNA or ESLA more profitable?

Do analysts recommend ERNA or ESLA?

Summary

How does Ernexa Therapeutics compare to Jasper Therapeutics?

Which has higher earnings & valuation, JSPR or ERNA?

Do analysts rate JSPR or ERNA?

Do insiders & institutionals have more ownership in JSPR or ERNA?

Which has more risk & volatility, JSPR or ERNA?

Does the media favor JSPR or ERNA?

Is JSPR or ERNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools